Preventive and Personalized Medicine (2021-2023)

Asfendiyarov Kazakh National Medical University1 site in 1 country400 target enrollmentMarch 23, 2022

ConditionsIdiopathic Scoliosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Idiopathic Scoliosis
Sponsor: Asfendiyarov Kazakh National Medical University
Enrollment: 400
Locations: 1
Primary Endpoint: Genotyping for the SNP associated with liver cirrhosis
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to identify genetic determinants of susceptibility to idiopathic scoliosis . It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of idiopathic scoliosis

Registry

clinicaltrials.gov

Start Date

March 23, 2022

End Date

January 20, 2023

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Asfendiyarov Kazakh National Medical University

Responsible Party

Principal Investigator

Ildar Fakhradiyev

Head of the Laboratory of Experimental Medicine

Asfendiyarov Kazakh National Medical University

Eligibility Criteria

Inclusion Criteria

•Persons with a doctor-confirmed diagnosis of idiopathic scoliosis;
•Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs;
•Hereditary history of scoliosis;
•Persons who are able and willing to provide written informed consent;

Exclusion Criteria

•Patients diagnosed with idiopathic scoliosis under 4 and over 40 years of age;
•Representatives of the Kazakh ethnic group less than 3 generations;
•No family history of bilateral idiopathic scoliosis;
•Patients with an acute period of the inflammatory process (laboratory and clinical signs);
•Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
•Pregnant or lactating women;
•Tuberculosis of any localization in the active phase and in history;
•Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
•Severe and decompensated course of endocrine diseases;
•Autoimmune diseases;